IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion

  • Authors:
    • Meng Liu
    • Ziyang Li
    • Weirong Yao
    • Xiaoping Zeng
    • Lingyun Wang
    • Jiao Cheng
    • Bingyu Ma
    • Ruiqian Zhang
    • Weiping Min
    • Hongmei Wang
  • View Affiliations

  • Published online on: November 12, 2019     https://doi.org/10.3892/mmr.2019.10816
  • Pages: 445-453
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies suggest that radiotherapy (RT) can induce immune activation, which not only reduces the progression of tumors, but also causes the release of tumor antigens. The combination of RT and immune checkpoint blockade, such as the inhibition of programmed cell death 1 (PD‑1) and programmed cell death ligand 1 (PD‑L1), has been demonstrated to yield impressive response rates. However, a substantial proportion of patients develop resistance such therapies. Previous studies have shown that indoleamine 2,3‑dioxygenase (IDO) causes T cell exhaustion and increased formation of regulatory T cells (Tregs), upregulating the expression of inhibitory receptors and ligands. Therefore, the application of IDO inhibitors combined with RT may have a synergistic effect by relieving immunosuppression. Lewis lung cancer cell‑bearing mice were treated with the IDO inhibitor 1‑methyl‑tryptophan (1MT) and/or 10 Gy RT. Tumor size was measured every day, flow cytometry was performed to measure the expression of dendritic cell (DC) maturation markers, inhibitory receptors, ligands, cytotoxic T cells and Treg phenotypic markers. Reverse transcription‑quantitative PCR was used to evaluate the mRNA expression levels of IDO, PD‑L1, PD‑1, T cell immunoglobulin domain and mucin domain 3 (TIM‑3), B‑ and T‑lymphocyte attenuator (BTLA) and galectin‑9. Compared with the control group, treatment with 1MT or RT reduced tumor growth, however, the combination therapy was more effective than either treatment alone. Flow cytometry showed the upregulation of CD80, CD86 and the major histocompatibility complex II in spleen DCs and the concurrent downregulation of CD4, CD25 and forkhead box protein P3 in lymphocytes in the treatment groups. Compared with the control group, inhibitory receptors and ligands that affect DCs and T cells were observed, expression levels of PD‑L1, PD‑1, TIM‑3, BTLA and galectin‑9 are decreased in treatment group compared with control. IDO inhibition synergized with RT to downregulate Tregs, inhibitory receptors and ligands to prevent T cell exhaustion. By activating DCs and T cells, this combination therapy may strongly enhance antitumor immunity and inhibit tumor progression.
View Figures
View References

Related Articles

Journal Cover

January-2020
Volume 21 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu M, Li Z, Yao W, Zeng X, Wang L, Cheng J, Ma B, Zhang R, Min W, Wang H, Wang H, et al: IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion. Mol Med Rep 21: 445-453, 2020
APA
Liu, M., Li, Z., Yao, W., Zeng, X., Wang, L., Cheng, J. ... Wang, H. (2020). IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion. Molecular Medicine Reports, 21, 445-453. https://doi.org/10.3892/mmr.2019.10816
MLA
Liu, M., Li, Z., Yao, W., Zeng, X., Wang, L., Cheng, J., Ma, B., Zhang, R., Min, W., Wang, H."IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion". Molecular Medicine Reports 21.1 (2020): 445-453.
Chicago
Liu, M., Li, Z., Yao, W., Zeng, X., Wang, L., Cheng, J., Ma, B., Zhang, R., Min, W., Wang, H."IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion". Molecular Medicine Reports 21, no. 1 (2020): 445-453. https://doi.org/10.3892/mmr.2019.10816